A tree-bark compound rewires gut bacteria to shut down colitis inflammation

Ulcerative colitis (UC) affects millions of people worldwide and, despite a growing arsenal of biologics, current therapies still fall short for many patients, with inflammatory bowel disease costing the US healthcare system more than $31 billion a year. New early-stage research published on Figshare points toward an unexpected ally: aucubin (AU), an iridoid glycoside isolated from the bark of Eucommia ulmoides, a traditional Chinese medicinal tree. The study describes a multi-step mechanism by which AU recruits a specific gut bacterium, triggers production of an anti-inflammatory metabolite, and together they switch off an enzyme that drives intestinal inflammation.

Aucubin enriches Adlercreutzia and restores equol in colitic mice

Working with a dextran sodium sulfate (DSS)-induced colitis mouse model, a widely used and reproducible system that mimics many hallmarks of human UC, the researchers gave colitic mice oral aucubin and then mapped what changed in the gut using integrated transcriptomics, 16S rRNA sequencing, and untargeted metabolomics. The most striking shift was in microbial composition: AU markedly enriched Adlercreutzia equolifaciens, a bacterium named for its ability to produce equol (EQ), an isoflavone-derived metabolite. Colitic mice had severely depleted equol levels, and AU treatment restored them. Both AU and EQ, the team found through microscale thermophoresis and surface plasmon resonance assays, directly bound argininosuccinate synthase 1 (ASS1), a central enzyme in arginine metabolism that is elevated in UC patients and worsens colitis when overexpressed.

ASS1 suppression reduces iNOS-driven gut inflammation

ASS1 sits upstream of a damaging cascade: when the enzyme is overactive, it feeds the arginine-mTOR-iNOS signaling axis, promoting excessive nitric oxide production and sustaining the inflammatory environment that erodes the colonic mucosa. Both AU and EQ, by directly inhibiting ASS1, suppressed this cascade and helped restore intestinal barrier integrity. The researchers validated the target with a neat pharmacological test: activating ASS1 with the compound LM2I fully abolished the therapeutic effects of both AU and EQ, confirming that ASS1 inhibition is not incidental but central to the mechanism. Equol's broad anti-inflammatory properties have been documented in prior reviews, but this study is among the first to map its role in colitis to a specific host enzyme.

Fecal transplants and oral equol reproduce aucubin's protection

To establish that the microbiota changes were causally protective and not merely correlative, the team performed fecal microbiota transplantation (FMT) from AU-treated donors into colitic recipient mice. The transplanted animals reproduced the protective phenotypes seen in AU-treated mice, including ASS1 suppression and restoration of arginine metabolic balance, despite never receiving AU themselves. Separately, direct oral administration of equol to colitic mice replicated AU's anti-colitis effects, reducing inflammation and repairing the gut barrier. Together, these two experiments close a mechanistic loop: AU enriches Adlercreutzia equolifaciens, the bacterium produces equol, equol inhibits ASS1, and the colitis resolves. As a metabolite produced by gut bacteria from soy isoflavone daidzein, equol's broader bioactivities including anti-inflammatory and barrier-protective effects have attracted interest across several disease models, lending additional plausibility to the current findings.

Limitations: mouse model, single research group, no human data yet

The study is squarely in the investigational category. All experiments were conducted in DSS-induced mouse colitis, and translating these findings to human UC will require substantial additional work. The active ingredient aucubin has shown anti-inflammatory effects in earlier in vitro and in vivo studies, but clinical evidence in humans remains absent. Equol production in the human gut is itself uneven: only a subset of people harbor sufficient equol-producing bacteria, meaning the AU-to-Adlercreutzia-to-EQ relay may not function equally across individuals. The study also comes from a single research group working with a preprint-style dataset repository, so independent replication will be an important next step before the mechanism can be considered established.

ASS1-targeting strategies open a new direction for colitis research

If the findings hold up, they reframe aucubin not merely as a botanical anti-inflammatory but as a microbiota modulator with a defined molecular target. Drugs that directly inhibit ASS1 could, in principle, bypass the microbiota dependency and reach patients who are not equol producers. Conversely, combining aucubin with probiotic Adlercreutzia equolifaciens supplementation could amplify equol production in patients who lack that microbial capacity. The AU-EQ-ASS1 axis also highlights arginine metabolism as a meaningful node in gut inflammation, a target that has been underexplored compared to the cytokine-blocking strategies behind most current biologics. For a disease that affects an estimated 6.8 million people globally, a new mechanistic handle is worth pursuing, even if the path from mouse colons to clinical trials remains long.

Evidence rating

INVESTIGATIONAL — 73/100

Caveats:

• All experiments were conducted in mice; no human data are presented.
• This study is currently a preprint deposited on Figshare and has not yet undergone peer review.
• Funding sources were not disclosed by the authors.
• Results have not been independently replicated.

Preclinical mouse study using a DSS-induced colitis model, integrating transcriptomics, metabolomics, 16S sequencing, and molecular binding assays alongside fecal microbiota transplantation to establish a step-by-step causal mechanism. Findings are associations validated pharmacologically in animals and cannot yet be extrapolated to humans. This is a single study that has not been independently replicated and, at the time of grading, has not undergone peer review.

References

1. 东京 刘 (2026). Gut microbiota-derived equol mediates the therapeutic effects of aucubin on DSS-induced colitis via inhibition of the ASS1/iNOS axis. Figshare. https://doi.org/10.6084/m9.figshare.32287935
2. Emerging Therapies in Inflammatory Bowel Disease: A Comprehensive Review – PMC. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10780447/
3. Chunhua Yang, Didier Merlin (2024). Unveiling Colitis: A Journey through the Dextran Sodium Sulfate-induced Model. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad312
4. Jiao‐Jiao Zhuo, Bing‐Juan Li, Meng‐Ran Tian (2026). Biological Activities, Health Benefits and Synthesis of Equol and Its Derivatives: A Comprehensive Review. Food Science & Nutrition. https://doi.org/10.1002/fsn3.71443
5. Hardeep Singh Tuli, Ajay Kumar, Katrin Sak, et al. (2022). Gut Microbiota-Assisted Synthesis, Cellular Interactions and Synergistic Perspectives of Equol as a Potent Anticancer Isoflavone. Pharmaceuticals. https://doi.org/10.3390/ph15111418
6. Kartini Kartini, Michelle Abigail Irawan, Finna Setiawan, Nikmatul Ikhrom Eka Jayani (2023). Characteristics, Isolation Methods, and Biological Properties of Aucubin. Molecules. https://doi.org/10.3390/molecules28104154